Lannett Cuts Deal With Celgene In Thalomid Antitrust Case
By Erin Coe · December 7, 2011, 2:47 PM EST
Lannett Co. Inc. on Tuesday resolved its antitrust suit in Pennsylvania federal court alleging Celgene Corp. unfairly blocked it from launching a generic version of Celgene's thalidomide-based cancer drug Thalomid....
To view the full article, register now.